Obinutuzumab

Obinutuzumab

Obinutuzumab GA101) is a glycoengineered Type II CD20 monoclonal antibody in development for non-Hodgkin lymphoma.

 

[accordions]
[accordion title= “Chemical Properties“]

Synonyms Obinutuzumab/afutuzumab
Molecular Weight 150 kDa
CAS No. 949142-50-1

[/accordion]

 

[accordions]
[accordion title= “References and Literature“]

[/accordion]